Q418 US Spine market remains fairly flat, rounding out a stable but unremarkable FY18.
Among the many topics covered in SmartTRAK's Q418/FY18 Spine Market Recap are:
- Q418, FY2018 Spine Market Highlights
- Spine Summit Insight
- Top 5 Players’ Q4 Performance
- Q418 Regulatory Highlights
At Spine Summit, BioMedGPS learned of one new trend in Spine insurer pushback: third party authorization, in which payers are farming out the prior authorization for high volume, high cost cases to one of a handful of companies (e.g. AIM, eviCore). Indeed, last year a Needham interview with spine surgeon Dr. Frank Valone indicated that payer headwinds now offset procedural volume growth in his practice. He reports that insurance providers have significantly increased scrutiny for procedures requiring implants. A different Spine surgeon reported an uptick in pre-authorization denials over the past year, but notes that the pushback has not increased to the levels of 2012-2013 when procedure volumes were declining. For his group it is impacting mostly multi-level degenerative lumbar cases and lumbar disc replacements, along with denial of specific line items and/or brands of products...
Read the entire Q418/FY18 Spine Market Recap including news, data and analysis*...
*This article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.
